Ken Griffin Morphic Holding, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $13,060 - $17,035	-500 Reduced 10.64%	4,200 $143,000
Q1 2024 May 15, 2024	SELL	$26.64 - $40.31 $210,456 - $318,449	-7,900 Reduced 62.7%	4,700 $165,000
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $756,105 - $1.17 Million	-37,900 Reduced 75.05%	12,600 $363,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $908,657 - $2.53 Million	42,600 Added 539.24%	50,500 $1.16 Million
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $308,970 - $558,990	-9,000 Reduced 53.25%	7,900 $452,000
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $410,958 - $769,302	15,800 Added 1436.36%	16,900 $636,000
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $26,554 - $33,407	1,100 New	1,100 $29,000

4.96M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.